Martin Auster
Stock Analyst at Raymond James
(2.52)
# 2,316
Out of 4,944 analysts
49
Total ratings
55.56%
Success rate
10.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Reiterates: Outperform | $370 → $424 | $432.52 | -1.97% | 1 | Aug 1, 2025 | |
| DYN Dyne Therapeutics | Reiterates: Outperform | $37 → $31 | $12.24 | +153.27% | 1 | Jul 29, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $58.30 | +105.83% | 7 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $28.97 | +262.44% | 7 | Mar 16, 2022 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | $26 | $6.84 | +280.12% | 1 | Mar 22, 2021 | |
| SLDB Solid Biosciences | Maintains: Neutral | $105 → $120 | $6.68 | +1,696.41% | 4 | Mar 16, 2021 | |
| GLTO Galecto | Maintains: Outperform | $725 → $300 | $3.36 | +8,828.57% | 2 | Mar 16, 2021 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $49 → $58 | $16.91 | +242.99% | 3 | Mar 10, 2021 | |
| UTHR United Therapeutics | Maintains: Outperform | $169 → $196 | $309.72 | -36.72% | 4 | Feb 22, 2021 | |
| ALXO ALX Oncology Holdings | Maintains: Outperform | $62 → $98 | $0.66 | +14,735.00% | 2 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $122.87 | -51.17% | 2 | Jan 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $31.98 | +103.25% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $20.40 | +257.84% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $5.50 | - | 2 | Dec 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $14.60 | +434.25% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.94 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $6.49 | +562.56% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $34 | $46.15 | -26.33% | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $11.00 | +90.91% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $20.74 | -22.84% | 1 | May 7, 2020 |
Alnylam Pharmaceuticals
Aug 1, 2025
Reiterates: Outperform
Price Target: $370 → $424
Current: $432.52
Upside: -1.97%
Dyne Therapeutics
Jul 29, 2025
Reiterates: Outperform
Price Target: $37 → $31
Current: $12.24
Upside: +153.27%
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $58.30
Upside: +105.83%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $28.97
Upside: +262.44%
Fulcrum Therapeutics
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $6.84
Upside: +280.12%
Solid Biosciences
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $6.68
Upside: +1,696.41%
Galecto
Mar 16, 2021
Maintains: Outperform
Price Target: $725 → $300
Current: $3.36
Upside: +8,828.57%
Stoke Therapeutics
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $16.91
Upside: +242.99%
United Therapeutics
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $309.72
Upside: -36.72%
ALX Oncology Holdings
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $0.66
Upside: +14,735.00%
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $122.87
Upside: -51.17%
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $31.98
Upside: +103.25%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $20.40
Upside: +257.84%
Dec 10, 2020
Downgrades: Underperform
Price Target: n/a
Current: $5.50
Upside: -
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $14.60
Upside: +434.25%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $1.94
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $6.49
Upside: +562.56%
Jul 7, 2020
Initiates: Outperform
Price Target: $34
Current: $46.15
Upside: -26.33%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $11.00
Upside: +90.91%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $20.74
Upside: -22.84%